NXP completes Aviva Links and Kinara acquisitions for $550 million.

Edesa Biotech's paridiprubart (EB05) demonstrated a 25% relative reduction in risk of death in a Phase 3 study for Acute Respiratory Distress Syndrome (ARDS). The treatment showed a clinically meaningful improvement in survival and recovery, with a consistent safety and tolerability profile. The study met primary and secondary endpoints with statistical significance.